Replies to post #176412 on Biotech Values

[biotech jim]

IMS, sorry for the late reply.

What’s your opinion of IMS’ expansion opportunities in emerging markets?

I do not have a good feel for this as I am not aware of the competitive landscape if any in emerging market companies. Also I do not have a good feel for how forward looking the emerging market companies are in their desire to use IMS type services. My bottom line on IMS is that it will remain a relatively slow growth company, on the order of high single digits.

When I made the comment on the global demographic tailwind, I meant that for my other ongoing new positions at the time of my post, that is energy companies/positions.

Wondering also whether you think GILD is a buy here, considering your position in ENTA and your prior comments on GILD's HIV franchise.